Xin Lang Cai Jing·2025-12-29 07:41Core Viewpoint - Shanghai Pharmaceuticals announced the board's approval to renew the framework agreement for daily related transactions with Yunnan Baiyao, effective from January 1, 2026, to December 31, 2026, with sales and procurement limits set at 1.2 billion and 700 million respectively [1] Group 1 - The agreement will allow Shanghai Pharmaceuticals to sell products to Yunnan Baiyao up to 1.2 billion and purchase products up to 700 million [1] - As of the announcement date, Yunnan Baiyao holds a 17.95% stake in Shanghai Pharmaceuticals, making it the second-largest shareholder [1] - In the first eleven months of 2025, Shanghai Pharmaceuticals reported sales to Yunnan Baiyao amounting to 605 million and purchases totaling 494 million [1]